^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Glioma |
| Drug: | Ojemda (tovorafenib) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Published date:
04/23/2024
Excerpt:
Day One Biopharmaceuticals Inc...announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
